Ceftriaxone resistant Salmonella Typhi carries an IncI1-ST31 plasmid encoding CTXM-15 by Djeghout, Bilal et al.
MQUO000000000 CROᴿ
MQUL000000000 CROᴿ
LT882486.1 CROᴿ
LT905060
AE014613.1
PRJEB7681
MQUM000000000 CROᴿ
PRJEB19771 CROᴿ
PRJEB21992 CROᴿ
AL513382
CAAU00000000.1 CROᴿ
MQUN000000000 CROᴿ
Figure Click here to download Figure Figures_Bilal_Typhi_Paper.pptx 

B.
A.
Table. Antimicrobial susceptibility phenotype and minimum inhibitory concentration (MIC) 1 
of the ceftriaxone-resistant S. Typhi isolated in Bangladesh. 2 
Antibiotic 
Zone diameter of 
inhibition (mm) 
MICs 
Interpretation 
(CLSI, 2016) 
Ampicillin 00 >256 μg/mL Resistant 
Chloramphenicol 26 4 μg/mL Sensitive 
Co-trimoxazole 32 0.023 μg/mL Sensitive 
Ciprofloxacin 36 0.012 μg/mL Sensitive 
Levofloxacin 35 Not done Sensitive 
Nalidixic acid 28 Not done Sensitive 
Azithromycin 18 4 μg/mL Sensitive 
Gentamicin 22 0.75 μg/mL Sensitive 
Ceftazidime 15 8 μg/mL Resistant 
Cefixime 00 Not done Resistant 
Ceftriaxone 00 >256 μg/mL Resistant 
Imipenem 32 Not done Sensitive 
Meropenem 34 <0.125 μg/mL Sensitive 
Tetracycline 26 1 μg/mL Sensitive 
 3 
 4 
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Sup. 1. Plasmids used as references for comparison in this study, selected by BLASTn against NCBI database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* No inc group detectable, no plasmid name   
Plasmid 
Accession 
number 
Inc- 
group 
Strain 
Percentage  of Identity (%)/ 
Detection of blaCTX-M15 + ISEcp1  
pESBL-EA11 
pEC_Bactec 
pHUSEC2011-1 
pMVAST0167_2 
pSE115 
pV150-a 
CP003290.1 
GU371927.1 
HE610900.2 
CP014494.1 
KT868530.1 
LC056403.1 
I1 
I1 
I1  
* 
I1 
I1 
Escherichia coli O104:H4 str. 2011C-3493 
Escherichia coli 
Escherichia coli HUSEC2011 
Escherichia colistr. MVAST0167 
Salmonella Enteritidis str. SE115 
Escherichia colistr. V150 
99% (100% coverage) 
99% (99% coverage) 
99% (100% coverage) 
99% (87% coverage) 
99% (98% coverage) 
99% (72% coverage) 
pHg 
pMS6198B 
pJIE101 
pKPN3-307 
pM16-13 
* 
CPOO6662 
CP015836.1 
EU418922 
KY271404.1 
KY751925 
LN794248 
N 
A/C 
F 
* 
FII 
HI2 
Klebsiella pneumoniae str. ATCC BAA-2146 
Escherichia colistr. MS6198 
Escherichia colistr. Tx101 
Klebsiellapneumoniaestr. Kp-48 
Klebsiellapneumoniaestr. M16-13 
Salmonella Typhimurium 
Mobile element detected 
Mobile element detected 
Mobile element detected 
Mobile element detected 
Mobile element detected 
Mobile element detected 
Supplementary Material Files
Sup. 2. Salmonella Typhi used for comparison  
Accession number  Year of isolation Country of isolation  Ceftriaxone 
susceptibility 
Plasmid 
MQUL00000000 2016 India R IncX3 
MQUM00000000 2016 India R IncX3 
MQUN00000000 2016 India R IncA/C2 
MQUO00000000 2016 India R IncX3 
LT882486.1 * Pakistan S * 
LT905060 * * S * 
AE014613.1 Ty2 Russia S No plasmids 
PRJEB7681 * * R * 
PRJEB19771 2015 DRC R * 
CAAU00000000.1 1998 Kenya R * 
AL513382 CT18 Vietnam S IncIH1 
 
*Data not found 
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Abstract 39 
Purpose: Ceftriaxone is the drug of choice for typhoid fever and the emergence of 40 
resistant Salmonella Typhi raises major concerns for treatment. There are an 41 
increasing number of sporadic reports of ceftriaxone resistant S. Typhi and limiting the 42 
risk of treatment failure in the patient and outbreaks in the community must be 43 
prioritised. This study describes the use of whole genome sequencing to guide 44 
outbreak identification and case management.   45 
Methodology: An isolate of ceftriaxone resistant S. Typhi from the blood of a child 46 
taken in 2011 at the Popular Diagnostic Center, Dhaka, Bangladesh was subjected to 47 
whole genome sequencing, using an Illumina NextSeq 500 and analysis using 48 
Geneious software. 49 
Results: Comparison with other ceftriaxone resistant S. Typhi revealed an isolate from 50 
the Democratic Republic of the Congo in 2015 as the closest relative but no evidence 51 
of an outbreak. A plasmid belonging to incompatibility group I1 (IncI1-ST31) which 52 
included blaCTX-M-15 (ceftriaxone resistance) associated with ISEcp-1 was identified. 53 
High similarity (90%) was seen with pS115, an IncI1 plasmid from S. Enteritidis, and 54 
with pESBL- EA11, an incI1 plasmid from E. coli (99%) showing that S. Typhi has 55 
access to ceftriaxone resistance through the acquisition of common plasmids. 56 
Conclusions: The transmission of ceftriaxone resistance from E. coli to S. Typhi is of 57 
concern because of clinical resistance to ceftriaxone, the main stay of typhoid 58 
treatment. Whole genome sequencing, albeit several years after the isolation, 59 
demonstrated the success of containment but clinical trials with alternative agents are 60 
urgently required. 61 
   62 
Introduction 66 
Infection with S. Typhi, the causative agent of typhoid fever, is the predominant 67 
invasive bacterial disease in many developing countries [1-3]. Estimates for the burden 68 
of typhoid fever in low to middle income countries, 7-48 million [4], suffer from gaps in 69 
the data but it is clear that India, Bangladesh and Pakistan shoulder a major burden 70 
[5,6]. Antibiotic treatment revolutionised the clinical management of typhoid fever, 71 
reducing mortality from around 30% to less than 1%, but antibiotic resistance has 72 
relentlessly followed the introduction of new drugs. Chloramphenicol, used through the 73 
1950’s and 60’s, was replaced in the 1970’s by cotrimoxazole and amoxicillin after 74 
chloramphenicol-resistant strains of S. Typhi emerged [7]. In the 1990’s multidrug 75 
resistant (MDR) S. Typhi emerged with resistance to all three first line drugs. Of 76 
concern was that the pathogenicity of S. Typhi [8] was linked to plasmid-encoded 77 
resistance [9] and that one MDR strain (H58) [10] which expanded globally [11,12] 78 
was associated with a single distinct plasmid type, IncHI1 PST6 (plasmid MLST type 79 
6) [13]. The spread and persistence of the MDR phenotype led to the recommendation 80 
of third generation cephalosporins (ceftriaxone) or fluoroquinolones (ciprofloxacin) as 81 
first line therapy [14]. In many low to middle income countries, ciprofloxacin (or 82 
ofloxacin) became the preferred choice for its oral formulation and affordable cost, 83 
compared with ceftriaxone. Typhoid cases are often treated empirically, with oral 84 
antibiotics in the community, and referred to hospital for parenteral therapies only 85 
when the patient fails to respond [15]. The widespread use of fluoroquinolones 86 
however led to the global emergence of strains with reduced susceptibility and then 87 
high level resistance [16]. Recommendations for the treatment of fluoroquinolone-88 
resistant S. Typhi are ceftriaxone or azithromycin. Azithromycin, a macrolide, is 89 
popular because of its oral formulation and single daily dose. However, rapid 90 
emergence of resistance to macrolides during treatment of other infections [17,18] has 91 
triggered opposition to its use for typhoid fever [19]. This leaves third generation 92 
cephalosporins as the most common, acceptable treatment but concern is growing 93 
that widespread resistance to this last line of treatment for typhoid fever will emerge. 94 
The relentless spread of extended spectrum beta-lactamases (ESBLs) in the 95 
Enterobacteriaceae, in particular CTX-M type ESBLs [20] predicts that these concerns 96 
will be realised and an H58-like ceftriaxone resistant S. Typhi will most likely, when it 97 
emerges, spread globally. To date, only sporadic reports of ceftriaxone-resistant S. 98 
Typhi have been published, mainly from Asia (including Japan) but also from West 99 
and southern Africa [21-26].  100 
In S. Typhi, plasmid-encoded resistance to cephalosporins remains rare, especially 101 
mediated by the successful BlaCTX-M-group of enzymes [27]. However, the diverse 102 
nature of the mobile elements now encoding ceftriaxone resistance combined with the 103 
selective pressure exerted by the widespread use of ceftriaxone across the sub-104 
continent suggest there is a real risk of an outbreak of ceftriaxone resistant typhoid 105 
fever. 106 
Here we report a comprehensive analysis of the full genome sequence of ceftriaxone-107 
resistant S. Typhi from Bangladesh and place both plasmid and chromosome into 108 
context. 109 
Materials and methods 110 
Bacterial Isolation and identification 111 
In 2001, an S. Typhi was isolated from a child’s blood sample in the microbiology 112 
laboratory of the Popular Diagnostic Center, Dhaka, Bangladesh, and sub-cultured on 113 
MacConkey agar. Identification was confirmed using API20E (bioMérieux, USA) and 114 
agglutination with Salmonella specific antisera (Ramel, Thermo Fisher Scientific, 115 
USA).  116 
Antimicrobial resistance profile 117 
Disk diffusion antibiotic susceptibility tests were carried out and interpreted according 118 
to the Clinical and Laboratory Standards Institute guidelines (CLSI - 2016) [28]. The 119 
following discs were used:  ampicillin (10 μg), cotrimoxazole (25 μg), chloramphenicol 120 
(30 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), nalidixic acid (30 μg), azithromycin 121 
(15 μg), gentamicin (10 μg), ceftazidime (30 μg), cefixine (5 μg), ceftriaxone (30 μg), 122 
imipenem (10 μg), meropenem (10 μg) and tetracycline (30 μg). Minimum inhibitory 123 
concentration (MIC) was determined using ETEST strips (bioMérieux-USA) (Table 1). 124 
The ability of the strain to produce beta-lactamase was determined via nitrocefin disc 125 
(Oxoid-UK).  126 
Whole Genome Sequencing (WGS) and in silico analysis 127 
DNA extracted from the S. Typhi isolate was converted into a Nextera XT library for 128 
sequencing on an Illumina NextSeq 500 platform according to the manufacturer’s 129 
instructions. The S. Typhi library was diluted to 4nM (as determined by analysis on an 130 
Agilent Technologies 2200 Tapestation and using the Qubit HS dsDNA assay) and 131 
pooled in equimolar amounts with other barcoded libraries. The entire library pool was 132 
then diluted to 1.8pM and sequenced using the NextSeq 500 v2 2x150bp paired-end 133 
protocol. 134 
The genome was assembled using Velvet defaults parameter [29]. The web-based 135 
tool SeqSero 1.0 was used to check the genetic serotype of the isolate [30]. The 136 
genome assembly was then subjected to sequence type (ST) analysis using 137 
Salmonella in Silico Typing Resource platform (SISTR) [31]. We interrogated the 138 
assembly for acquired resistance genes [32], Salmonella Pathogenicity Islands (SPI) 139 
[32], plasmids and incompatibility group using Res.Finder [32], SPIFinder-1.0 (CGE 140 
online platform – checked with Geneious R10 [33]) and PlasmidFinder-1.3 [34] 141 
respectively. The presence of SPI-7 was confirmed by mapping the genome against 142 
a published SPI-7 sequence [accession number NC_004631.1] to detect the tviA gene 143 
540 bp; the first gene in SPI-7 and sopE, the major type three secretion system (TTSS) 144 
effector protein was necessary. Comparison of the background strain was carried out 145 
using  Geneious Tree Builder, Neighbour-Joining default parameters [33]. The 146 
following genome sequences were used to build a rooted phylogenetic tree, H is used 147 
to define clonal groups or ”haplotypes” of S. Typhi: H10 [accession number 148 
AE014613.1], H55 [CAAU00000000.1] and [PJREB19771], H58 isolates, 149 
[NZ_LT8882486.1], [LT905060] and [PRJEB7681], CT18, H1 (root) [AL513382], 150 
Plasmid MLST profiling for the IncI1 group of plasmids was performed using the 151 
pMLST-1.4 Server [34]. Geneious R10 software [33]  was used for plasmid mapping  152 
with the map to reference functions. The plasmid sequences listed in Table 2 were 153 
obtained from NCBI and used as references for comparison. A nucleotide BLAST was 154 
performed on BLAST Ring Image Generator (BRIG) [35] in order to build a circular 155 
comparative figure with different selected references against the S. Typhi plasmid 156 
found in this study. 157 
 158 
Results and Discussion 159 
Microbiological Identification 160 
The isolate agglutinated with specific antisera O9 and Hd and was confirmed as S. 161 
Typhi by API 20E (Profile: 4404540).  162 
Antimicrobial Resistance Phenotype 163 
The isolate was sensitive to chloramphenicol, cotrimoxazole, ciprofloxacin, 164 
levofloxacin, nalidixic acid, azithromycin, imipenem, gentamicin, meropenem, and 165 
tetracycline. It was resistant to ampicillin, ceftazidime, cefixime and ceftriaxone. Zone 166 
diameters and minimum inhibitory concentrations (MICs) are provided in Table 1. 167 
Ceftriaxone is the mainstay of typhoid fever treatment in Bangladesh, and indeed 168 
globally, and so the resistance of this isolate was immediately flagged and tracking of 169 
this strain given a high priority – comparison of resistance profiles was the only method 170 
available in the hospital until recently and no similar isolate has been identified. This 171 
is the second ceftriaxone-resistant S. Typhi reported from Bangladesh, but the first 172 
isolate (found in 1999 [22]) had been lost, preventing direct comparison. Ceftriaxone-173 
resistant S. Typhi is rarely reported in the literature but cases are increasing. So, to 174 
allow tracking of this strain and to identify clonal expansion (i.e. emergence of an 175 
outbreak strain) whole genome sequencing was performed. 176 
In silico analysis of the chromosome 177 
The isolate was S. Typhi multi-locus Sequence Type 2 (ST2) (Table 3).  The isolate 178 
contained the pathogenicity islands (SPIs) normally associated with S. Typhi: SPI-1, 179 
2, 5, 7 and 8, required for systemic infection and intracellular pathogenesis. The full 180 
genome sequence is available for comparison with other ceftriaxone-resistant S. Typhi 181 
at the ENA (EMBL-EBI) [project PRJEB21992]. Analysis for antimicrobial resistance 182 
genes revealed that aminoglycoside resistance genes were present and that clinically 183 
important beta-lactam resistance was mediated by blaTEM-1B and blaCTX-M-15 184 
genes (Table 3). Comparison with other published ceftriaxone resistant isolates of S. 185 
Typhi revealed a close relationship only with an isolate from the Democratic Republic 186 
of the Congo [36] (Fig. 1); so this isolate represents a sporadic case. Four Isolates 187 
recently reported from India [26] highlight the importance of using chromosomal 188 
background and plasmid content – of three ceftriaxone resistant isolates of S. Typhi 189 
reported as harbouring IncX plasmids two are closely related but one is very different 190 
– thus an  outbreak definition using plasmids only would falsely include the isolate 191 
annotated MQUN in Figure 1.  192 
The isolate reported in this study harboured one plasmid of incompatibility group I1. 193 
IncI1 plasmids are normally associated with E. coli, only rarely seen in Salmonella. 194 
We therefore investigated the origins of this plasmid and associated mobile elements.  195 
Genetic characterization of the incI1-ST31 plasmid identified in S. Typhi 196 
The plasmid [pPRJEB21992] was identified as IncI1-ST31. Comparison with another 197 
IncI1 salmonella plasmid carrying blaCTX-M-15: pS115 from S. Enteritidis, revealed 198 
high sequence similarity 70-100% over large stretches of DNA (Fig. 2). Subsequent 199 
searching revealed full length, near 100% matches of the new S. Typhi plasmid with 200 
plasmid IncI1 pESBL-EA11 from E. coli [CP003290.1] – present in the shiga-toxin 201 
positive enteroaggregative E. coli from a large outbreak in Germany in 2011 [37]. Two 202 
more E. coli plasmids: pEC_Bactec [GU371927.1] from E. coli isolated from the joint 203 
of a horse suffering from arthritis in Belgium [38];  and pHUSEC2011 [HE610900.2] 204 
(reported as epidemic plasmid in E. coli strain HUSEC2011 in Germany, but not 205 
published), appeared to be identical plasmids (Fig. 2) from remote sources, suggesting 206 
that the plasmid is transmitted between E. coli. 207 
The blaCTX-M-15 was detected within a mobile element which mapped to an IncHI2 208 
plasmid from S. Typhimurium and other plasmids listed in table 2, and was adjacent 209 
to the insertion sequence ISEcp-1 (Fig. 3). The mobile element ISEcp-1 is commonly 210 
associated with CTX-M-1539 and is present on many plasmid backbones [38, 40] and 211 
so we interrogated the databases for the mobile element. IncN pHg from Klebsiella 212 
pneumoniae [CP006662], IncF pJIE101 from E. coli [EU418922], incFII pM16-13 from 213 
Klebsiella pneumoniae [KY751925], and incHI2 pKST313 from S. Typhimurium  214 
[LN794248] belonged to different incompatibility groups, but all carried the blaTEM-215 
CTX-M-15 gene complex associated with ISEcp-1 (Fig. 2) showing the widespread 216 
nature this mechanism of CTX-M-15 dissemination can have. 217 
The IncI1 plasmid reported here in S. Typhi, not commonly seen in Salmonella, was 218 
contained in Bangladesh (and so may have a biological cost in the S. Typhi bacterial 219 
host) but the clear transmissibility of the ISEcp-1 element is a matter of concern [41]. 220 
When chloramphenicol resistance first emerged in S. Typhi, the phenotype was 221 
associated with a cost [42] but the continued selective pressure allowed the co-222 
evolution of plasmids and large outbreaks of MDR typhoid fever [43].  223 
Plasmids belonging to incompatibility group I1 are widely spread in 224 
Enterobacteriaceae. They are known to have carried β-lactamase genes and type IV 225 
pili encoded genes, responsible for resistance to beta lactams and virulence 226 
respectively. Bacteria carrying plasmids of this group are known to be more 227 
pathogenic than commensal strains [44, 45] Inc I1 plasmids carrying bla-CTX-M-15 228 
were previously identified in England [46], Pakistan, Honduras (in E. coli of human and 229 
animal origin), S. Anatum, S. Infantis, S. Ohio and S. Typhimurium [47], Inc FII plamids 230 
carrying the blaCTX-M-15 gene is present in S. Enteritidis [47] Given this diversity of 231 
opportunity for S. Typhi to pick up CTX-M-15 it seems likely that if we continue the 232 
widespread use of ceftriaxone for the treatment of typhoid fever then a plasmid 233 
carrying resistance, probably encoded by blaCTX-M-15, will find a compatible S. Typhi 234 
host and this combination will eventually emerge and cause outbreaks. Were this to 235 
happen, it would leave us with very few treatment options for typhoid fever. It is of 236 
great clinical importance that sequence data from Ceftriaxone resistant S. Typhi is 237 
shared and that efforts to limit the spread of ceftriaxone resistant strains are supported. 238 
In particular treatment trials with alternative antibiotics should be funded immediately.  239 
Conclusion 240 
Here we report the whole genome sequence of a second ceftriaxone-resistant S. Typhi 241 
strain isolated in Bangladesh. It has, again, been contained, but the emergence of two 242 
different strains shows that selective pressure is widespread.  A similar strain in the 243 
DRC several years later with the same mobile element on a different plasmid also 244 
demonstrates the pressure of antibiotic selection and also suggests that the ISEcp1- 245 
CTX-M-15 mobile element is becoming established in the S. Typhi population. It is 246 
only a matter of time until the CTX-M-15 gene appears in a successful plasmid-247 
chromosome background as happened with S. Typhi H58 and pST6. Given the 248 
dependence of typhoid treatment on ceftriaxone, the tracking of ceftriaxone-resistant 249 
S. Typhi is crucial and we encourage any laboratory isolating ceftriaxone-resistant S. 250 
Typhi to report as swiftly as possible to allow the potential outbreak to be contained. 251 
Rapid sequencing of genomes is now well established in many countries and 252 
comparison of any new isolates with results from others is routine for accredited 253 
reference labs such as the UK’s Gastrointestinal Bacteriology Reference Laboratory. 254 
Sequence data however, needs to be generated in a useful time frame.  255 
A global outbreak, as with S. Typhi H58, of MDR-ESBL-expressing S. Typhi has the 256 
potential to be catastrophic and must be identified as quickly as possible so that 257 
patients can be treated with active antibiotics (e.g. the carbapenems or penems) but 258 
these expensive drugs are not yet licenced for typhoid fever; they must be tested and 259 
made available for containment. Any ceftriaxone treatment failure must be dealt with 260 
promptly using alternatives - treatment trials with alternative agents and control of 261 
outbreaks through vaccination are urgently needed. 262 
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 416 
  417 
Figure 1. Phylogenetic tree based on single nucleotide polymorphism of whole-418 
genome alignments of S. Typhi strains.  Strains are annotated with the accession 419 
number of the sequencing data. The tree was carried out using Geneious Tree Builder, 420 
Neighbour-Joining default parameters. Juke-Cantor was used as distance model 421 
calculator 33. The scale below the tree represents numbers of substitutions divided by 422 
the length of the sequence 423 
Figure 2. Pairwise comparisons of IncI1 plasmid identified in S. Typhi in this study (ring 424 
4, green). This figure shows plasmid pESBL_EA11 compared against six other 425 
plasmids (the full list of plasmid sequences is described in table 2). Ring 2 and 3 show 426 
GC and skew content respectively. The remaining rings show nucleotide BLAST 427 
comparison of the six plasmids against pESBL_EA11. 428 
Figure 3. Pairwise comparisons of plasmids from different Incompatibility groups 429 
encoding blaCTX-M-15 and ISEcp1 genes. (A) This figure shows plasmid pESBL_EA11 430 
compared against eight other plasmids (the full list of plasmid sequences is described in table 431 
2). Ring 2 and 3 show GC and skew content respectively. The remaining rings show nucleotide 432 
BLAST comparison of the eight plasmids against pESBL_EA11. (B) Focus on the sequence 433 
region encoding blaCTX-M-15 plus the insertion sequence ISEcp1; on the same plasmids 434 
from (A) respectively. Geneious R10 software was used for multiple alignment of these 435 
plasmids.  The black thick line represents the consensus sequence. The blue bar represents 436 
the coverage. The green thick line represents the identity of the alignment. Sequences of each 437 
plasmid are represented in grey tick lines with base pairs numbers on. In yellow are the 438 
annotated genes.    439 
